Global /United States /Healthcare /Drug Manufacturers - General /PLX

Protalix BioTherapeutics, Inc.

PLX

• NYSEAMERICAN: PLX • Delayed

2.12USD 0%

As of 13 June 2026, Protalix BioTherapeutics, Inc. has a market cap of $170.81M USD, ranking #22049 globally and #3554 in the United States. It ranks #1983 in the Healthcare sector, and #715 in the Drug Manufacturers - General industry.

Global Rank

22049

Country Rank

3554

Sector Rank

1983

Industry Rank

715

Key Stats

Market Cap

$170.81MUSD

Enterprise Value

$149.67MUSD

Revenue (TTM)

$52.74MUSD

EBITDA (TTM)

-$4.04MUSD

Net Income (TTM)

-$6.6MUSD

EBITDA Margin

-7.7%

Profit Margin

-13%

Forward PE

9.9

PS Ratio

3.3

PB Ratio

3.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Dror Bashan open_in_new

Employees

226

Founded

1993

IPO

15 May 1998

Website

protalix.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-4.3%	-0.7%	3.2%	-7.6%	18%	-25%	-24%	-46%

News

PLX Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NYSE American (NYSEAMERICAN / AMEX) MIC: XASE PRIMARY	PLX Protalix BioTherapeutics Inc ISIN: US74365A3095 Shares Out.: Shares Outstanding: 80.572M¹ Shares Float: 77.447M² TV: TradingView: AMEX: PLX SA: Stock Analysis: NYSEAMERICAN: PLX YF: Yahoo Finance: PLX GF: Google Finance: NYSEAMERICAN: PLX NQ: NASDAQ: PLX BA: Barron's: PLX MS: Morningstar: XASE: PLX	2.12 USD	TV: TradingView: AMEX: PLX SA: Stock Analysis: NYSEAMERICAN: PLX YF: Yahoo Finance: PLX GF: Google Finance: NYSEAMERICAN: PLX NQ: NASDAQ: PLX BA: Barron's: PLX MS: Morningstar: XASE: PLX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 446K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 320K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 211K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 160K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 87K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 69K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 188K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 169K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 161K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 106K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 64K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 63K%	14.6	United Kingdom

chevron_leftBack